Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011
Authors
LaRocque, Regina C.Rao, Sowmya R.
Lee, Jennifer S.
Ansdell, Vernon
Yates, Johnnie A.
Schwartz, Brian S.
Knouse, Mark
Cahill, John
Hagmann, Stefan
Vinetz, Joseph
Connor, Bradley A.
Goad, Jeffery A.
Oladele, Alawode
Alvarez, Salvador
Stauffer, William
Walker, Patricia
Kozarsky, Phyllis
Frankco=Paredes, Carlos
Dismukes, Roberta
Rosen, Jessica
Hynes, Noreen A.
Jacquerioz, Frederique
McLellan, Susan
Hale, Devon
Sofarelli, Theresa
Schoenfeld, David A.
Marano, Nina
Brunette, Gary
Jentes, Emily S.
Yanni, Emad
Sotir, Mark J.
Ryan, Edward T.
UMass Chan Affiliations
Department of Quantitative Health SciencesDocument Type
Journal ArticlePublication Date
2011-12-07Keywords
AdolescentAdult
Aged
Aged, 80 and over
Child
Child, Preschool
Communicable Disease Control
Communicable Diseases
Demography
Female
Humans
Infant
Male
Middle Aged
Public Health Administration
Public Health Informatics
Risk Assessment
*Travel
Travel Medicine
United States
Young Adult
Epidemiology
Health Services Research
Public Health
Metadata
Show full item recordAbstract
BACKGROUND: International travel poses a risk of destination-specific illness and may contribute to the global spread of infectious diseases. Despite this, little is known about the health characteristics and pretravel healthcare of US international travelers, particularly those at higher risk of travel-associated illness. METHODS: We formed a national consortium (Global TravEpiNet) of 18 US clinics registered to administer yellow fever vaccination. We collected data regarding demographic and health characteristics, destinations, purpose of travel, and pretravel healthcare from 13235 international travelers who sought pretravel consultation at these sites from January 2009 through January 2011. RESULTS: The destinations and itineraries of Global TravEpiNet travelers differed from those of the overall population of US international travelers. The majority of Global TravEpiNet travelers were visiting low- or lower-middle-income countries, and Africa was the most frequently visited region. Seventy-five percent of travelers were visiting malaria-endemic countries, and 38% were visiting countries endemic for yellow fever. Fifty-nine percent of travelers reported >/=1 medical condition. Atovaquone/proguanil was the most commonly prescribed antimalarial drug, and most travelers received an antibiotic for self-treatment of travelers' diarrhea. Hepatitis A and typhoid were the most frequently administered vaccines. CONCLUSIONS: Data from Global TravEpiNet provide insight into the characteristics and pretravel healthcare of US international travelers who are at increased risk of travel-associated illness due to itinerary, purpose of travel, or existing medical conditions. Improved understanding of this epidemiologically significant population may help target risk-reduction strategies and interventions to limit the spread of infections related to global travel.Source
Clin Infect Dis. 2012 Feb 15;54(4):455-62. Epub 2011 Dec 5. Link to article on publisher's siteDOI
10.1093/cid/cir839Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46592PubMed ID
22144534Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1093/cid/cir839
Scopus Count
Related items
Showing items related by title, author, creator and subject.
-
COVID-19 Travel Restrictions and the International Health Regulations - Call for an Open Debate on Easing of Travel RestrictionsPetersen, Eskild; McCloskey, Brian; Hui, David S.; Kock, Richard; Ntoumi, Francine; Memish, Ziad A.; Kapata, Nathan; Azhar, Esam I.; Pollack, Marjorie; Madoff, Lawrence C.; et al. (2020-04-17)The COVID-19 pandemic caused by the novel coronavirus (SARS-CoV-2) has made national governments worldwide to mandate several generic infection control measures such as physical distancing, self-isolation, and closure of non-essential shops, restaurants schools, among others. Some models suggest physical distancing would have to persist for 3 months to mitigate the peak effects on health systems and could be required on an intermittent basis for 12 to 18 months (Flaxman et al., 2020).
-
Restaurant List: Wuss-taah, Paris of the Millennium (2019-2020)Ennis, Michael (2019-10-01)List of restaurants in the Worcester, MA, area compiled by Michael Ennis M.D. for the University of Massachusetts Medical School community. This list of restaurants highlights the best examples of Worcester's culinary scene.
-
Identification of fully human monoclonal antibodies against the adhesin domain of colonizing factor antigen I of Escherichia coliSedic, Maja; Wisheart, Danielle; Ejemel, Monir; Stoppato, Matteo; Giuntini, Serena; Barry, Eileen; Thomas, William D.; Klempner, Mark S.; Wang, Yan (2016-05-20)Enterotoxigenic Escherichia coli (ETEC) causes significant diarrheal illness in infants in the developing world and travelers to endemic countries including military personnel. Infection of the host involves bacterial colonization of the small intestinal epithelium and toxin secretion leading to watery diarrhea. CFA/I is the most common colonizing factor antigens expressed on the surface of ETEC isolates. The CFA/I adhesin, CfaE, appears to be required for ETEC binding to human intestinal cells for colonization. Human antibodies against the binding domain of CfaE have potential to block colonization of ETEC and serve as a potent immunoprophylactic therapeutic for ETEC-related diarrhea. In the current study, we generated a panel of fully human monoclonal antibodies (HuMabs) against the adhesin domain of CfaE using mice transgenic for human immunoglobulin genes and identified lead antibodies utilizing a series of in vitro assays. Mice were immunized with the N-terminal binding domain of CfaE fused to maltose binding protein. Over thirty unique IgG1 HuMabs were identified with binding activity to recombinant CfaE. These antibodies were tested for inhibition of hemagglutination of type A human erythrocytes by ETEC. Two lead HuMabs, 837-6 and 840-53, inhibited hemagglutination at low concentrations (< 1 nM). Both antibodies also blocked the binding of ETEC with intestinal epithelial cells. Biacore analysis revealed an affinity of less than 2 nM with distinct epitopes of CfaE. Our analysis suggests that CfaE specific HuMabs 837-6 and 840-53, as the first isolated fully human monoclonal antibodies against CfaE adhesion domain, could potentially be used in combination with heat labile toxin neutralizing antibodies to prevent traveler’s diarrhea.